Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
281-300 of 1,743 trials

Nicotinamide for Liver Fibrosis in Type 2 Diabetes

We are studying whether nicotinamide can help slow liver fibrosis in people with type 2 diabetes. The trial will also assess safety and other health factors related to obesity.

Hepatic Fibrosis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesDiabetologyEndocrinologyHepatology

Fibrodysplasia Ossificans Progressiva: INCB000928 Study

We are testing a new medication, INCB000928, to see if it can prevent new bone growth in people with Fibrodysplasia Ossificans Progressiva. The study will also evaluate the safety and tolerability of this treatment.

Fibrodysplasia Ossificans Progressiva>2 yearsEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineOrthopedics and Traumatology

Breast Cancer: Stopping CDK4/6 Inhibitors

We are studying whether stopping CDK4/6 inhibitors helps maintain disease stability in patients with metastatic HR positive, HER2 negative breast cancer. This trial involves patients who have had stable disease after long-term treatment.

Metastatic HR Positive, HER2 Negative Breast Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

HER2-Negative Breast Cancer: Pembrolizumab and Radiation Therapy

We are studying a new treatment combining immunotherapy and radiation for patients with HER2-negative breast cancer who haven't responded to initial chemotherapy. The goal is to see if this approach improves cancer response and quality of life.

HER2 Negative Breast Cancer>2 yearsEfficacy phase (II)Standard MedicinesOncology

Alpelisib for Lymphatic Malformations with PIK3CA Mutation

We are studying whether alpelisib can improve symptoms and imaging results in adults and children with lymphatic malformations caused by a PIK3CA mutation. Participants will be compared to those receiving a placebo to assess the treatment's effectiveness.

Lymphangioma>2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Advanced Ovarian Cancer: Comparing Treatment Combinations

We are studying two different drug combinations to see which one helps patients with advanced ovarian cancer live longer without disease progression after surgery. This trial involves patients who have undergone complete initial surgery.

Advanced Ovarian Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Metastatic Melanoma: Diclofenac with PD-1 Inhibitor

We are studying whether adding diclofenac to ongoing PD-1 inhibitor therapy helps patients with metastatic melanoma who have stable disease. This trial aims to evaluate the potential benefits of this combination treatment.

Metastatic Melanoma>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesDermatologyOncology

Long-Term Follow-Up for Gene-Modified T Cell Treatment

We are monitoring patients treated with gene-modified T cells to assess any delayed side effects and the long-term effectiveness of the treatment. This study also looks at the health of younger patients who received this therapy.

Malignant Lymphoid Neoplasm>2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal MedicineOncology

Community-Acquired Pneumonia: Customized Antibiotic Duration Study

We are investigating whether a new strategy for shortening antibiotic treatment is as effective as standard care for hospitalized patients with pneumonia. This study aims to improve patient outcomes while reducing unnecessary antibiotic use.

Community-acquired Pneumonia>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesInternal MedicinePulmonology

Prostate Cancer: AZD5305 Treatment Study

We are studying whether AZD5305, combined with standard hormonal treatments, can improve outcomes for men with metastatic castration-sensitive prostate cancer. This trial compares the new treatment to a placebo to assess its effectiveness.

Metastatic Castration-Sensitive Prostate Cancer>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteOncologyUrology

Autoimmune Encephalitis: Satralizumab Study

We are testing the effectiveness and safety of satralizumab in patients with NMDAR or LGI1 mediated autoimmune encephalitis. The study aims to see if it improves disability and reduces symptoms compared to a placebo.

Autoimmune Encephalitis>2 yearsConfirmation phase (III)Post-Trial Drug AccessPartially RemoteNeurologyRheumatology

Urothelial Cancer: BT8009 Treatment Study

We are investigating whether the new drug BT8009, alone or with pembrolizumab, can help patients with advanced urothelial cancer live longer and respond better than standard chemotherapy.

Locally Advanced or Metastatic Urothelial Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyUrology

Neuroblastoma: ABTL0812 Treatment for Children

We are testing a new drug, ABTL0812, in children with relapsed or refractory neuroblastoma and other solid tumors. The study aims to find the best dose and evaluate its safety and effectiveness when used alone or with other therapies.

Relapsed/Refractory Neuroblastoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncologyPediatrics

Small Cell Lung Cancer: BI 764532 Treatment Study

We are testing different doses of BI 764532 in patients with relapsed small cell lung cancer and other neuroendocrine cancers. The goal is to see if this treatment can help improve outcomes for those who have not responded to prior therapies.

Small Cell Lung CancerNeuroendocrine CarcinomaLarge Cell Neuroendocrine Carcinoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Cancer Treatment Continuation Study

We are offering ongoing treatment for cancer patients who participated in earlier studies. This study checks the safety of the therapy while ensuring patients have access to their treatment.

Cancer Treatment Continuation>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Multiple Myeloma: Elranatamab Treatment Study

We are studying the effectiveness of Elranatamab for patients with relapsed or refractory multiple myeloma who have already been treated with three different drug classes. This trial aims to see if it can help achieve better disease control.

Multiple Myeloma>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Fetal and Neonatal Alloimmune Thrombocytopenia: Nipocalimab Study

We are testing nipocalimab in pregnant individuals at risk of FNAIT to see if it can lower the chances of severe complications for the baby. This study compares the treatment to a placebo to evaluate its effectiveness.

Neonatal Alloimmune Thrombocytopenia>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsInfectious Diseases

Advanced Non-Small Cell Lung Cancer: Zongertinib Study

We are testing whether zongertinib (BI 1810631) can improve outcomes for patients with advanced non-small cell lung cancer with HER2 mutations compared to standard treatment options.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

HER2-Positive Breast Cancer: GLSI-100 Treatment Study

We are testing a new peptide treatment for patients with HER2-positive breast cancer at high risk of recurrence after standard therapies. The study aims to see if it improves outcomes compared to a placebo.

Breast CancerHER2 Positive Breast Cancer>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteOncology

Advanced Cancer: SOT201 Treatment Study

We are evaluating the safety and effectiveness of SOT201 in patients with advanced or metastatic cancer. This study aims to see how well this treatment works compared to current options.

Advanced or Metastatic Solid Tumors>2 yearsSafety phase (I)Oncology